Camidanlumab tesirine is a Monoclonal Antibody Conjugated owned by ADC Therapeutics, and is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing.
Camidanlumab tesirine acts by targeting CD25 (IL-2 receptor alpha chain or TAC). CD25 is a cell-surface antigen, which is over-expressed in tumor cells. On binding with CD25 the therapeutic candidate may activate natural killer (NK) cells and macrophages and may induce T cell cytotoxic immune responses against tumor cells. It induces a long-lived adaptive immune responses against tumor-associated antigens and limits the growth of cancer cells.
The revenue for Camidanlumab tesirine is expected to reach a total of $382m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Camidanlumab tesirine NPV Report.
Camidanlumab tesirine Overview
Camidanlumab tesirine is under development for the treatment of CD25-expressing relapsed/refractory Hodgkin lymphoma, relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms, Non-Hodgkin lymphoma. The therapeutic candidate is administered as an intravenous infusion. ADCT-301 is an antibody drug conjugate composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug–antibody ratio of 2.3. It was also under development for prostate cancer, relapsed or refractory CD25-positive acute lymphocytic leukemia (ALL). It was under devlopment for the treatment of advanced solid tumors including head and neck squamous cell carcinoma, fallopian tube cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, pancreas cancer, bladder cancer, renal cell carcinoma, melanoma, triple-negative breast cancer, ovarian cancer and colorectal cancer
ADC Therapeutics Overview
ADC Therapeutics, is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat solid tumors and hematological cancers. It is investigating Loncastuximab Tesirine (Lonca), an ADC composed of a humanized monoclonal antibody against B-cell hematological tumors; and Camidanlumab Tesirine (Cami) for the treatment of solid tumors. It is also developing ADCT-602 drug for B-cell acute lymphoblastic leukemia; ADCT-601 targeting AXL in solid tumors; ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors; and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and acute myeloid leukemia. The company is a spin-off from Spirogen Ltd. ADC Therapeutics is headquartered in Lausanne, Switzerland.
The company reported revenues of (US Dollars) US$33.9 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$261.7 million in FY2021, compared to an operating loss of US$219.3 million in FY2020. The net loss of the company was US$230 million in FY2021, compared to a net loss of US$246.3 million in FY2020. The company reported revenues of US$76.3 million for the third quarter ended September 2022, compared to a revenue of US$17.3 million the previous quarter.
Quick View – Camidanlumab tesirine
|Highest Development Stage|